Bharat Book

US Cancer Generics Market Outlook

Press Release   •   Feb 27, 2017 13:57 IST

US Cancer Generics Market Outlook 2022 report gives comprehensive insight on the various indicators and trend analysis related to the emergence and integration of cancer generics drugs in mainstream pharmaceutical market in US. The introduction of generics has resulted in saving of billions of dollars for various stake holders involved US cancer drug market. It is expected that total savings from generics in cancer therapy (in treatment & post treatment) will surpass US$ 30 Billion by 2022 and will further give the required thrust to adoption of generics drugs in cancer therapy as compare to prescribed branded drugs.

Even though most of the attention and spending in the oncology segment in the US has been focused on the remarkable scientific inventions of the newer targeted drugs but the overburdening of the economic high cost of cancer drugs has made US to follow up the line of generics. Certainly, after the existence of Hatch-Waxman Act, the entries of generic products were acceptable between the Americans.

The beneficial aspects of generic regimens are already well established, as the delivery of equal therapeutic efficacy in low price is the principal aim of cancer generics. The cost for patented oncological drugs and the generic drugs have wide gap which is getting shorter with the emerging patent cliff for cancer drugs in US and the arrival of the cancer generics era.

Concerning the cost, indeed cancer generics provide an exceptional solution towards high cost, yet the scenario is different for the Americans. However, in US cancer generics cost much higher in contrary to the other nations, reason being is the no negotiation mode of government in the pharmaceutical sector. The prices paid for generics in US are many fold higher than developing countries like India and China.

Certainly, among the developed nations the usage and prescription of generics is quite higher depicting the greater medical needs due to overburden of massive diseases and cancer is one of them. The demand for cancer generics is so high that the trend has created a shortage landscape. It is a part of the problem of the scarcity of generics across all medical specialties, but its oncology is particularly vulnerable. The reason of the shortages is multi-factorial but is largely economic and is due to the lack of incentives to produce generics.

US Cancer Generics Market Outlook 2022 report highlights:

  • Introduction to Cancer Generics
  • US Generic Drugs Legislature
  • US Health Insurance Scenario & Cancer
  • Aspects of Branded & Non-Branded Generics
  • US Cancer Generics Market Overview

    Table of Contents

    1. Cancer Generics: A Modest Regimen
    2. US Generic Drugs Legislature
    3. Trail towards Patenting of Cancer Generic Drugs
    4. Economic Burden of Prescription Drugs in US
    5. Cancer Generic Drugs: Still Overpriced in US Market
    6. US Health Insurance Scenario & Cancer
    7. Aspects of Branded & Non-Branded Generics
    8. Generics in Oncology World
    9. FDA Approved Anti-Cancer Generics in US
    10. US Cancer Generics Market Overviews

    For More Related ReportsHealthcare Market Research Reports

    Contact us at:

    Bharat Book Bureau
    Tel: +91 22 27810772 / 27810773
    Email: poonam@bharatbook.com
    Our Blog:https://www.bharatbook.com/blog/
    Follow us on Facebook:https://www.facebook.com/BharatBook3B
    Follow us on Twitter:
    https://twitter.com/researchbook
    Follow us on Linked In: http://www.linkedin.com/company/bharat-book-bureau

  • Bharat Book Bureau, the leading market research information aggregator provides market research reports, company profiles, country reports, newsletters, and online databases for the past twenty four years to corporate, consulting firms, academic institutions, government departments, agencies etc., globally, including India. Our market research reports help global companies to know different market before starting up business / expanding in different countries across the world.